COVID-19 Vaccination and Incidence of Pediatric SARS-CoV-2 Infection and Hospitalization.

ABSTRACT:

Importance

A SARS-CoV-2 vaccine was approved for adolescents aged 12 to 15 years on May 10, 2021, with approval for younger age groups following thereafter. The population level impact of the pediatric COVID-19 vaccination program has not yet been established.

Objective

To identify whether California's pediatric COVID-19 immunization program was associated with changes in pediatric COVID-19 incidence and hospitalizations.

Design, setting, and participants

A case series on COVID-19 vaccination including children aged 6 months to 15 years was conducted in California. Data were obtained on COVID-19 cases in California between April 1, 2020, and February 27, 2023.

Exposure

Postvaccination evaluation periods spanned 141 days (June 10 to October 29, 2021) for adolesc

SUBMITTER: Head JR 

PROVIDER: S-EPMC11040406 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature